Ipilimumab variant with enhanced ADCC
US10196445B1 · kind B1 · utility
12Cited by
5References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2016 |
| Grant date | Feb 5, 2019 |
| Priority date | — |
| Expiry date | Sep 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-CTLA-4 antibodies having enhanced ADCC activity, and their use in treating cancer. In one embodiment, the anti-CTLA-4 antibody is ipilimumab, and ADCC activity is enhanced by introducing G236A, S239D, A330L and I332E mutations (“GASDALIE”) into the Fc region of the heavy chain constant domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.